8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

      Date of Report (Date of earliest event reported):  January 11, 2002

                               US ONCOLOGY, INC.
             (Exact name of registrant as specified in its charter)

         Delaware                      0-26190                  84-1213501
(State or other jurisdiction    (Commission File Number)      (IRS Employer
     of incorporation)                                   Identification Number)

        16825 Northchase Drive
             Suite 1300
           Houston, Texas                                         77060
(Address of principal executive offices)                        (Zip Code)

                                (832) 601-8766
             (Registrant's telephone number, including area code)


ITEM 5. OTHER EVENTS

     On January 11, 2002, US Oncology, Inc. issued a press release announcing
that it proposes to make a private placement of approximately $175 million in
senior subordinated notes. The press release is filed as Exhibit 99.1 to this
Current Report on Form 8-K, and the contents of such exhibit are incorporated
herein by reference.

ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS

        (c) Exhibits.

            Exhibit
            Number    Description
            ------    -----------
             99.1     Press release of U.S. Oncology, Inc., dated January 11,
                      2002

                                  SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934,
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                 US ONCOLOGY, INC.

Date:  January 11, 2002          By:    /s/ Phillip H. Watts
                                    --------------------------------------
                                 Name:  Phillip H. Watts
                                 Title: Vice President and
                                        General Counsel


                               INDEX TO EXHIBITS

                                                                 SEQUENTIALLY
EXHIBIT                                                            NUMBERED
NUMBER                      DESCRIPTION                              PAGE
- -------                     -----------                          -------------
 99.1         Press release of US Oncology, Inc. dated
              January 11, 2002

EX-99.1

FOR IMMEDIATE RELEASE

CONTACT:
Carlos Arcos                            Alvis R. Swinney
Fogarty Klein Monroe                    US Oncology
713.867.3187                            832.601.6174
carcos@fkmagency.com                    alvis.swinney@usoncology.com

US ONCOLOGY TO MAKE PRIVATE PLACEMENT OF $175 MILLION SENIOR SUBORDINATED NOTES

HOUSTON, January 11, 2002 -- US Oncology, Inc. (NASDAQ:USON) proposes to make a
private placement of approximately $175 million in senior subordinated notes to
repay currently outstanding senior debt and for other general business purposes.
The company anticipates closing the offering later this month or early February.

        This news release does not constitute an offer to sell or the
solicitation of an offer to buy securities. The offering is being made only to
qualified institutional buyers. The securities have not been registered under
United States or state securities laws, and may not be offered or sold in the
United States absent registration or an applicable exemption from the
registration requirements.

This press release contains forward-looking statements, including statements
that include the words "believes," "expects," "anticipates," "estimates,"
"intends," "plans," "projects," or similar expressions and statements regarding
our prospects. All statements other than statements of historical fact included
in this press release are forward-looking statements. Although the company
believes that the expectations reflected in such statements are reasonable, it
can give no assurance that such expectations will prove to have been correct.
Please refer to the company's filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for 2000 and subsequent SEC
filings, for a more extensive discussion of factors that could cause actual
results to differ materially from the company's expectations.

                                      ###